Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378964 | 0.86 | MAOB (0.60) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 | |
| SCHEMBL5861986 | 0.82 | MAOB (0.56) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 | |
| SCHEMBL12164223 | 0.82 | MAOB (0.67) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 | |
| SCHEMBL8581165 | 0.81 | MAOB (0.43) | MAOBHDAC1PPARGPPARDFFAR1 | |
| SCHEMBL25082599 | 0.80 | MAOB (0.53) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 | |
| SCHEMBL203850 | 0.80 | PPARG (0.62) | PPARGPPARDFFAR1PPARA | |
| SCHEMBL204961 | 0.80 | PPARG (0.62) | PPARGPPARDFFAR1PPARA | |
| SCHEMBL12615157 | 0.79 | MAOB (0.63) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 | |
| SCHEMBL29478296 | 0.79 | MAOB (1.00) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 | |
| SCHEMBL2400347 | 0.79 | MAOB (1.00) | MAOBSIGMAR1CYP19A1HTR1AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | MAOB 1856/4885SIGMAR1 98/4885CYP19A1 1966/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | MAOB 1378/4885SIGMAR1 82/4885CYP19A1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.